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Abstract
Background: Human fetal adrenal glands are highly active and, with the placenta, regulate circulating progesterone,
estrogen and corticosteroids in the fetus. At birth the adrenals are essential for neonate salt retention through
secretion of aldosterone, while adequate glucocorticoids are required to prevent adrenal insufficiency. The objective
of this study was to carry out the first comprehensive analysis of adrenal steroid levels and steroidogenic enzyme
expression in normal second trimester human fetuses.
Methods: This was an observational study of steroids, messenger RNA transcripts and proteins in adrenals from up to
109 second trimester fetuses (11 weeks to 21 weeks) at the Universities of Aberdeen and Glasgow. The study design
was balanced to show effects of maternal smoking.
Results: Concentrations of 19 intra-adrenal steroids were quantified using liquid chromatography and mass
spectrometry. Pregnenolone was the most abundant steroid while levels of 17α-hydroxyprogesterone,
dehydroepiandrosterone sulphate (DHEAS) and progesterone were also high. Cortisol was present in all
adrenals, but aldosterone was undetected and Δ4 androgens were low/undetected. CYP17A1, CYP21A2 and
CYP11A1 were all highly expressed and the proteins localized to the adrenal fetal zone. There was low-level
expression of HSD3B and CYP11B2, with HSD3B located mainly in the definitive zone. Maternal smoking altered fetal
plasma adrenocorticotropic hormone (ACTH) (P = 0.052) and intra-adrenal progesterone, 17α-hydroxyprogesterone and
16α-hydroxyprogesterone, but not plasma or intra-adrenal cortisol, or intra-adrenal DHEAS. Fetal adrenal GATA6 and
NR5A1 were increased by maternal smoking.
Conclusions: The human fetal adrenal gland produces cortisol but very low levels of Δ4 androgens and no detectable
aldosterone throughout the second trimester. The presence of cortisol in fetal adrenals suggests that adrenal
regulation of circulating fetal ACTH remains a factor in development of congenital adrenal hyperplasia during
the second trimester, while a relative lack of aldosterone explains the salt-wasting disorders frequently seen in
extreme pre-term neonates. Finally, maternal smoking may alter fetal adrenal sensitivity to ACTH, which could
have knock-on effects on post-natal health.
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Background
The human fetal adrenal gland develops initially as part
of the adrenogonadal primordium and is distinct in the
human by 7–8 weeks of gestation. The adrenals secrete
cortisol in response to adrenocorticotropic hormone
(ACTH) as early as week 8 of gestation [1], although the
main steroids produced in fetal life are dehydroepian-
drosterone (DHEA) and its sulphate (DHEAS), which
act as substrates for placental estrogen production [2].
Together, the fetal adrenal glands and placenta dominate
human fetal steroid endocrinology in a manner seen
only in higher primates. Normal development and func-
tion of the fetal adrenals is also essential for several pro-
cesses that can affect the fetus itself or the health of the
neonate. For example, disruption of the fetal adrenals
can lead to disorders of sex development [3], while fetal
misprogramming of the stress axis, through altered fetal
cortisol secretion, may predispose to diseases in later life
[4]. The adrenal glands are also essential for survival
early in post-natal life through the secretion of aldoster-
one, which prevents salt-wasting disorders [5], while
adequate cortisol is required to prevent adrenal insuffi-
ciency in the newborn [6]. Interestingly, pre-term neo-
nates are prone to salt-wasting disorders, which may
indicate a failure of aldosterone synthesis in fetal life or
altered sensitivity to the steroid [5]. Despite the import-
ance of the adrenal glands for fetal and post-natal health,
however, their development during fetal life in the hu-
man is not well described or understood. Animal models
are of limited relevance due to significant species differ-
ences in fetal adrenal structure, steroidogenic pathways
and endocrinology of pregnancy. However, only a limited
number of studies have examined the human fetal adrenal
directly ([1, 7–11] and in review [12, 13]). Consequently,
we have examined human fetal adrenal steroidogenesis
during the second trimester in a large number of well-
documented, normal, human fetuses. This includes the
first comprehensive liquid chromatography (LC)/mass
spectrometry (MS) analysis of human fetal adrenal steroid
levels during the second trimester.
Maternal smoking during pregnancy remains a signifi-
cant public health issue, as it can disrupt normal fetal pro-
gramming and can have irreversible effects on the post-
natal life of the offspring [14]. Cigarette smoke contains
many potential toxicants (e.g. heavy metals, aldehydes, ni-
trosamines and polycyclic aromatic hydrocarbons) [15]
that can cross the placental barrier to reach the fetus.
However, mechanisms behind the long-term effects of
smoking on the human fetus remain largely unknown.
Maternal smoking can affect fetal adrenal function and
development of the hypothalamo-pituitary-adrenal (HPA)
axis [16], which may be one mechanism by which smok-
ing programmes later health deficits of the offspring [17,
18]. We have, therefore, extended our developmental
study to examine the effects of maternal smoking on hu-
man fetal adrenal steroidogenesis.
Methods
Sample collection
The collection of fetal material involved in the adrenal
studies was approved by the National Health Service
(NHS) Grampian Research Ethics Committees (REC 04/
S0802/21). Human fetal kidneys were collected under a
separate, newer ethics permission as part of the Scottish
Advanced Fetal Research (SAFeR) Study. This was ap-
proved by NHS Grampian Research Ethics Committees
(REC 15/NS/0123). In all cases, women seeking elective
terminations of pregnancy were recruited with full writ-
ten, informed consent by nurses working independently
of the study at the Aberdeen Pregnancy Counselling Ser-
vice. Maternal data, medications used and self-reported
number of cigarettes smoked per day were recorded.
Only fetuses from normally progressing pregnancies (de-
termined at ultrasound scan prior to termination) from
women over 16 years of age and between 11 and
21 weeks of gestation (7 and 20 weeks for fetal kidneys)
were collected following termination by RU486 (mife-
pristone) treatment (200 mg) and prostaglandin-induced
delivery, as detailed previously [19]. Fetuses were trans-
ported to the laboratory within 30 min of delivery,
weighed, sexed and the crown-rump length recorded.
Blood samples were collected by cardiac puncture ex
vivo and plasma prepared in heparin-coated tubes was
stored at –80 °C. Fetal tissues were snap-frozen in liquid
nitrogen and stored at –80 °C or fixed in 10% neutral
buffered formalin. Adrenal samples were analysed in
four groups: control female, smoke-exposed female, con-
trol male and smoke-exposed male, with groups bal-
anced as far as possible for gestational age (Table 1).
Maternal smoking status was confirmed by measure-
ment of fetal plasma cotinine using a commercially avail-
able kit (Cozart Plc, Abingdon, Kent, UK). Fifty-six fetal
kidneys were analysed as a single group and as four
groups: control female, smoke-exposed female, control
male and smoke-exposed male.
Plasma measurements of hormones and binding globulins
Assays were performed using plasma samples from 60 sec-
ond trimester fetuses. Plasma ACTH levels were measured
(25 μL/fetus) using a single Milliplex® MAP Human Pituit-
ary Magnetic Bead Panel 1 kit (ACTH, growth hormone
(GH), thyroid-stimulating hormone (TSH), ciliary neuro-
trophic factor (CNTF), agouti-related protein (AGRP);
Millipore Limited, Watford, UK) and analysed using a Bio-
Plex200 system (Bio-Rad Laboratories Ltd, Hemel Hemp-
stead, UK). Intra- and inter-assay coefficients of variation
were < 10% and < 15% respectively, sensitivity was 0.91 pg/
mL and cross-reactivity was negligible. Cortisol was
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measured in 50 μL of plasma/fetus using a DetectX® Corti-
sol Enzyme Immunoassay kit (Arbor Assays, Ann Arbor,
MI, USA). Cross-reactivity with other steroids was < 8%,
sensitivity was 17.3 pg/mL and inter- and intra-assay coeffi-
cients of variation were 5.4% and 8.1% respectively.
Corticosteroid-binding globulin (CBG) concentrations were
measured by an established ligand-saturation assay [20].
Protein, DNA and RNA extractions
To avoid sampling error due to heterogeneous morph-
ology of the adrenal gland, only whole human fetal ad-
renal glands were homogenized in the presence of
protease inhibitors (Protease Inhibitor Cocktail, Sigma-
Aldrich Company Ltd, Gillingham, UK). Protein, DNA
and RNA were extracted from total tissue homogenates
with Qiagen AllPrep DNA/RNA/Protein mini kits
(Qiagen Ltd, Crawley, UK). RNA was extracted from
whole human fetal kidneys in the same way.
Intra-adrenal steroid quantification with LC/MS
Steroids were extracted from the unused, combined,
flow-through fractions of the Qiagen AllPrep DNA/
RNA/protein extraction protocol and quantified by LC/
MS. This approach was taken to maximize the data
gathered from as many fetuses as possible and reflects
the unique nature and relative scarcity of the human
fetal samples.
Steroid extractions
Initially, we determined whether intra-adrenal steroid
levels could be accurately measured from the unused
flow-through fractions of the Qiagen AllPrep DNA/
RNA/protein extraction protocol. The first studies, using
Table 1 Morphological data for the mothers and fetuses involved in adrenal studies
Population Characteristic Female fetuses Male fetuses
Control Smoke-exposed Control Smoke-exposed
Total adrenal samples N 29 19 31 30
Maternal indices Age (years) 25.5 ± 1.2 23 ± 1.2 23.8 ± 1.06 26.2 ± 1
Body mass index (BMI, kg/m2) 24.1 ± 0.8 26 ± 1.3 26 ± 0.95 25.8 ± 1.2
Cigarettes/day 0 ± 0 9.3 ± 0.7 0.2 ± 0.2 10.2 ± 1
Fetal indices Age (weeks) 14.6 ± 0.4 14.3 ± 0.8 14.6 ± 0.6 14.6 ± 0.5
Weight (g) 77 ± 13.3 75.4 ± 14.1 83.4 ± 12 91.8 ± 12.9
Crown-rump length (CRL, mm) 98.7 ± 5.2 95.1 ± 5 101.4 ± 4.3 105.5 ± 5.5
Ponderal index (weight, g/[CRL, cm3]) 70.2 ± 6.7 72.8 ± 5.4 68.8 ± 3.3 63.2 ± 1.8
Plasma cotinine (ng/mL) 6.8 ± 3.3 30.2 ± 5.4 5.3 ± 1.2 41.6 ± 6.4
Sub-population: plasma steroidsa N 14 16 13 17
Maternal indices Age (years) 24.3 ± 1.7 23.2 ± 1.3 24.5 ± 1.8 24.7 ± 1.2
BMI (kg/m2) 23.5 ± 1.2 23.8 ± 1.3 26.2 ± 1.4 25.3 ± 1.4
Cigarettes/day 0 ± 0 11 ± 1.3 0 ± 0 12.5 ± 1.1
Fetal indices Age (weeks) 15.6 ± 0.6 15.2 ± 0.6 15.2 ± 0.6 15.1 ± 0.6
Weight (g) 104.8 ± 19.9 93.6 ± 16.7 101.7 ± 22.5 97.1 ± 19.3
CRL (mm) 109.3 ± 7.7 106.9 ± 5.7 108 ± 7.4 107.2 ± 7.4
Ponderal index (weight, g/[CRL, cm3]) 64.9 ± 2.6 64 ± 2.6 73.9 ± 4.7 65 ± 2
Plasma cotinine (ng/mL) 3.3 ± 1.2 41.6 ± 2.8 2.6 ± 0.9 48.6 ± 2.2
Sub-population: mRNA/protein/steroidsa N 15 15 15 15
Maternal indices Age (years) 24.7 ± 1.6 23.2 ± 1.4 22.9 ± 1.3 26.6 ± 1.4
BMI (kg/m2) 24.2 ± 0.8 26.5 ± 1.4 26.23 ± 1.5 24.6 ± 1.6
Cigarettes/day 0 ± 0 8.8 ± 0.8 0 ± 0 12 ± 1.3
Fetal indices Age (weeks) 15.3 ± 0.6 15.1 ± 0.6 15.2 ± 1.2 15.2 ± 0.6
Weight (g) 97 ± 19.5 84.8 ± 17 94.9 ± 18.8 94.7 ± 19.9
CRL (mm) 106.4 ± 6.8 97.4 ± 6.1 104.3 ± 6.9 102.3 ± 8.7
Ponderal index (weight, g/[CRL, cm3]) 66.5 ± 2.3 75.5 ± 6.7 72 ± 4.6 67 ± 3.1
Plasma cotinine (ng/mL) 7.6 ± 4.6 30.2 ± 5.4 4 ± 1.5 50.9 ± 5.7
aAlthough there is some overlap between the two study sub-populations, not all plasma samples were from fetuses where the adrenal glands were collected.
Therefore, the two populations were not analysed together
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a [3H]-testosterone recovery standard with mouse ad-
renal tissue homogenate, showed that 72% of testoster-
one was recovered in the discardable flow-through
fraction from the protein precipitation step (step 15 of
the Qiagen manual) with 89.6% total recovery from the
total combined waste fractions. In further preliminary
studies using LC/MS, the recovery of intra-adrenal ste-
roids (from human fetal adrenals) was measured by
comparison of steroid levels in the initial tissue lysate
with levels in recovered fractions after RNA/DNA/pro-
tein extraction. Steroids were recovered primarily in the
protein precipitation step (step 15 in the Qiagen pro-
tein/DNA/RNA extraction protocol), with the exception
of DHEAS, which was recovered in all fractions. Esti-
mates of steroid recovery efficiencies from combined
fractions were as follows: cortisol 87%, androstenedione
122%, 17α-hydroxyprogesterone 113%, 21-deoxycortisol
87%, 11-deoxycortisol 111% and DHEAS 56%. These
data show that most steroids could be recovered from
tissues with high efficiency during Qiagen extraction.
For subsequent studies all of the residue fractions from
the Qiagen extraction process (steps 8, 15, 21 and 22)
were combined and extracted.
Three deuterated steroids (15 ng) were added as in-
ternal standards (ISs) prior to steroid extraction, as de-
scribed below. Steroids in the combined residue
fractions were extracted twice using ethyl acetate (4:1 ra-
tio to sample volume), subjected to a solid-phase extrac-
tion using 1 mL Strata-X, 33 μm polymeric reverse
phase cartridges (Phenomenex, Torrance, CA, USA) and
dissolved in a final volume of 150 μL methanol. The per-
centage recovery of all steroids through ethyl acetate
and solid phase extractions was > 82%, and the percent
relative standard deviation (RSD; n = 6) of all steroid
measurements was between 1.82 and 8.75%.
The standards prepared in methanol were not signifi-
cantly different than those prepared using the extraction
matrix, while recovery and percent RSD showed negli-
gible differences. We therefore used standards in metha-
nol for further experiments.
Intra-adrenal steroid quantification with LC/MS
Steroids were separated by reversed phase LC on an Ul-
tiMate 3000 RSLCnano (Thermo Fisher Scientific, Wal-
tham, MA, USA) separation system, using an Accucore™
PFP LC column with trimethyl silane (TMS) endcapping
(50 mm, 2.1 mm, 2.6 μm, Thermo Fisher). For both posi-
tive and negative modes, the mobile phase was a mixture
of solvents A (1% formic acid in water) and B (49:49:2
methanol:acetonitrile:isopropanol). Steroids were eluted
at a flow rate of 0.4 mL/min, using a linear gradient
from 24% B to 47% B in 2.0 min, followed by a linear
gradient to 66% B in 2.7 min and a subsequent linear
gradient to 100% B in 0.1 min. Elution at 100% B was
maintained for 0.9 min before lowering it to 24% B over
0.1 min and equilibrating the column for 2.5 min. The
total run time was 8.3 min and the injection volume was
5 μL.
Steroids were detected with a Q Exactive Orbitrap
(Thermo Fisher) mass spectrometer, using full-scan de-
tection (250–500 m/z). Table 2 contains a summary of
the limits of quantification for all steroids in this study.
For each sample, one MS run was completed at full scan
in positive mode and another MS run at full scan in
negative mode. MS mode was found to be more suited
for steroid profiling with the Orbitrap MS system, and
the sensitivities were similar to those achieved using LC-
MS/MS with a triple quadrupole MS system [21].
All instruments were controlled by Chromeleon soft-
ware (Thermo Fisher), and data acquisition, peak integra-
tion and quantification were performed using Xcalibur 2.2
software (Thermo Fisher). Calibration curves were used to
quantify the steroids, using the ratio of the steroid peak
area relative to the peak area of a specific deuterated IS
that had similar elution time and/or chemical properties.
Deuterated cortisol (4-pregnen-11β,17,21-triol-3,20-dione-
9,11,12,12-d4; Steraloids, Newport, RI, USA) was used
as the IS for aldosterone, cortisol, cortisone, cortico-
sterone, 11-deoxycortisol, cortisone sulphate, cortico-
sterone sulphate, 11-dehydrocorticosterone and Δ5-
androstenediol. Deuterated progesterone (4-pregnen-
3,20-dione-2,2,4,6,6,17α,21,21,21-d9; Steraloids) was used
as the IS for DHEA, 17α-hydroxypregnenolone, 17α-
hydroxyprogesterone, 16α-hydroxyprogesterone, testoster-
one, deoxycorticosterone, progesterone, pregnenolone and
Δ4-androstenedione. Deuterated DHEAS (5-androsten-
3β-ol-17-one-16,16-d2, sulphate, sodium salt; Steraloids)
was used as the IS for DHEAS. Calibration curves were
constructed from the LC/MS analyses of six to nine cali-
brator samples in the range of 1–2000 ng/mL. Calibrator
samples contained all three deuterated ISs at a concentra-
tion of 100 ng/mL, as well as steroid standards at relevant
concentrations from a dilution series in methanol. Ster-
oid standard stocks, from which the calibrator dilution
series were made, were all sourced from Sigma-Aldrich
or Steraloids.
To determine limits of detection (LODs) and limits of
quantification (LOQs), calibrator samples (n = 13) were
prepared at concentrations ranging from 0.01 ng/mL to
10,000 ng/mL, containing all of the steroids and deuter-
ated ISs at a fixed concentration of 100 ng/mL. These
were prepared in both methanol and Qiagen buffer mix-
ture. Calibration curves were generated by performing
least-squares regression analysis on peak area ratios rela-
tive to the IS at different concentrations, within the sensi-
tivity range of each steroid. The LOD and LOQ were
defined as the lowest steroid concentration with a signal-
to-noise ratio (S/N) larger than 3 and 10 respectively.
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Real-time reverse transcription polymerase chain reaction
(RT-PCR)
Messenger RNA (mRNA) from 60 human fetal adrenals
was reversed transcribed using random hexamers and
Superscript III (Life Technologies, Paisley, UK) [19, 22,
23]. Real-time RT-PCR was performed using Brilliant II
SYBR Green Master Mix (Agilent Technologies, Santa
Clara, CA, USA) and an MX3000 cycler (Stratagene,
Amsterdam, the Netherlands). mRNA levels were
expressed relative to two housekeeping genes (HKGs),
TATA box binding protein (TBP) and Phosphomannomu-
tase 1 (PMM1), which were identified as the optimal
HKGs from a total of six HKGs tested using NormFin-
der [24]. Data are expressed as the geomean of values
relative to each HKG multiplied by 103. NR3C2 tran-
script levels in human fetal kidneys were measured by
real-time PCR using LightCycler 480 SYBR Green I
Mastermix (Roche, Basel, Switzerland) and a Roche
LightCycler 480 and were expressed relative to ACTB.
All primers were designed as previously described [22];
the sequences are reported in Table 3. Primers designed
to amplify HSD3B recognized both type 1 and type 2
isoforms of the enzyme.
Immunohistochemistry
Adrenal sections (5 μm) were dewaxed and rehydrated,
and antigen retrieval was carried out in citrate buffer
(PT Module Buffer 1; Thermo Fisher) using a bench top
autoclave. Endogenous peroxidase activity was quenched
using DAKO Real™ peroxidase block (Agilent Technolo-
gies), and 20% Normal Goat Serum (Vector Laboratories,
Burlingame, CA, USA) was used to block non-specific
binding sites. The primary antibodies were for detection
of CYP11A1 (non-commercial rabbit polyclonal antibody
(gift from A.H. Payne)), CYP17A1 (non-commercial rabbit
polyclonal antibody (gift from I. Mason)), CYP21A2 (poly-
clonal rabbit antibody (Sigma;HPA048979)) and HSD3B
(non-commercial rabbit antibody which recognizes both
HSD3B1 and HSD3B2 (gift from I. Mason)). The second-
ary antibody used was Polyclonal Goat anti-Rabbit Im-
munoglobulin Horseradish Peroxidase (HRP) (DAKO;
Agilent Technologies). Signal amplification was necessary
only for HSD3B detection and was carried out using the
TSA Plus DNP (HRP) System (PerkinElmer, Waltham,
MA, USA). Visualization was by 3,3’-diaminobenzidine
(DAB) (DAKO Real™, Agilent Technologies) and sections
were counterstained with hematoxylin. For double im-
munofluorescence of CYP11A1 and CYP21A2, sections
were dewaxed, antigen-retrieved, blocked and probed with
CYP11A1 primary antibody as above. Antibody detection
was carried out with Goat anti-rabbit HRP (DAKO
(P0450); 1:1000 in phosphate-buffered saline (PBS))
followed by use of the Tyramide-TSA™ Plus Fluorescein
kit (PerkinElmer). Antigen retrieval was repeated in order
to denature the first set of antibodies. Sections were then
re-probed with CYP21A2 primary antibody as above with
detection by Alexa Fluor 594 (red) goat anti-rabbit (1:1000
in TBS) and counterstained with ToPro®-3-iodide (Invitro-
gen; Select FX™ Nuclear Labeling Kit; S33025). Confocal
images were captured using a Zeiss LSM 710 microscope
and ZEN software (Carl Zeiss Microimaging, LLC, Thorn-
wood, NY, USA).
Western blotting
Proteins were separated by sodium dodecyl sulphate
(SDS) gel electrophoresis using a XCell4 SureLock™
Midi-Cell apparatus (Life Technologies). Protein samples
(30 μg) in NuPAGE® LDS Sample Buffer, containing
NuPAGE® Sample Reducing Agent, were loaded to a
NuPAGE® 4–12% Bis-Tris Midi Protein Gel (Life Tech-
nologies). Electrophoresis was carried out in NuPAGE®
MOPS SDS Running Buffer, and the separated proteins
were transferred to nitrocellulose using the Invitrogen
iBlot® system and iBlot® Transfer Stacks (Life Technolo-
gies). Blocking was carried out using Odessey® Blocking
Buffer (PBS; LI-COR, Cambridge, UK). Membranes were
probed overnight with one of a number of primary anti-
bodies diluted in Odyssey buffer. The primary antibodies
used were anti-CYP11A1, anti-HSD3B, anti-CYP17A1
and anti-CYP21A2, as used for immunohistochemistry,
and anti-β-actin (monoclonal mouse antibody (ab8226;
Table 3 Primers used for RT-qPCR
Forward Reverse
CYP11A1 tttttgcccctgttggatgca ccctggcgctccccaaaaat
CYP11B1 tgtgtgatgctgccggagga cgcaatcggttgaagcgcc
CYP11B2 aggtggacagcctgcatccctg gcacatctgggttcagccgc
CYP17A1 ccatttcctgaacgcaccgg agagaggccaaggaaacagggct
CYP21A2 cggacctgtccttgggagactactcc ctgggctctcatgcgctcaca
DAX1
(NR0B1)
cctcccaggtccaagccatcaa tgagttccccactggagtccct
GATA6 aataattccattcccatgactccaacttc aatacttgagctcgctgttctcggg
HSD3Ba ccacaccgcctgtatcattgatgtct taggagttgggcccggctacct
MC2R tcttccacgcactgcggtacc catcagcgggaacagcgacg
MRAP cacagacatggccaacgggac agcaccacgaaggcagccag
PMM1 aacatctcgcccatcggcc tcaaagctgatcatgcctcctcg
POR ttttcagcatgacggacatgattctgt tttcttcatcttttccacaaagctgctc
SF-1
(NR5A1)
tcccttctgccgcttccagaaat tgaagccattggcccgaatct
STAR ggctggcatggccacagact ttgggcagccaccccttga
SULT2A1 caagatgtccaattattccctcctgagtgt tctcgaggaagatctgccatcttctc
TBP aggaaaaaattgaatagtgagacgagttcca tggactaaagatagggattccgggagt
NR3C2 tggcctggatgtggttggatttagg agaaacttgaccccaccgtctttcc
ACTB ttcctgggcatggagtcctgtg ttgatcttcattgtgctgggtgcc
aAmplifies both HSD3B1 and HSD3B2
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Abcam, Cambridge, UK)). Bound antibody was detected
with fluorescent secondary antibody (Cross Adsorbed,
DyLight conjugated secondary antibodies; Thermo
Fisher) and scanned using an Odyssey CLx-0565 Imager
(LI-COR). Bands were quantified using Image Studio
software (LI-COR).
Statistical analysis
A general linear model was used to examine the effects of
age, sex, smoking and any interactions between these fac-
tors on mRNA transcript, protein and steroid levels. The
data were modelled by a quasi-Poisson distribution to ac-
count for over-dispersion. The minimal adequate model
was used followed by Tukey’s post hoc analysis for factor-
ial variables. Levene’s test was used to compare variability
between groups. Statistical analysis was performed using
R Studio (Boston, MA, USA). For statistical analysis of ad-
renal steroids, measurements below the LOQ for each
steroid were substituted with a value of 0.
Results
Fetal plasma levels of adrenal-related hormones
ACTH, cortisol and CBG were detectable in fetal plasma
(using a sub-population of samples, see Table 1)
throughout the second trimester (Fig. 1). Levels of
ACTH and cortisol did not change significantly during
this period, but CBG showed a significant decrease be-
tween 12 and 20 weeks of gestation (Fig. 1c; P = 0.038).
Hormone levels did not differ significantly according to
fetal sex. Maternal smoking was associated with altered
levels of ACTH (Fig. 1a; interaction between age and
smoking, P = 0.052) with levels generally higher towards
the start of the second trimester. Levels of cortisol
(Fig. 1b) and CBG (Fig. 1c) were similar between control
and smoke-exposed fetuses.
Fetal adrenal steroid content
Overall fetal adrenal weight increased exponentially dur-
ing the second trimester (P < 0.001) with no difference
between sexes or due to maternal smoking (Fig. 1d).
Intra-adrenal steroid concentrations (measured in a sub-
population of the total, see Table 1) during the same
period are shown in Fig. 2, arranged within relevant ste-
roidogenic pathways. Pregnenolone was the most abun-
dant steroid found in the human fetal adrenal (Fig. 2)
with high levels of 17α-hydroxyprogesterone, DHEAS
and progesterone also present. Cortisol levels were vari-
able but were present in all samples. In contrast, aldos-
terone was not detectable in any samples, although
deoxycorticosterone and corticosterone were present.
Androstenedione was also undetectable in all samples,
although this may be related to a relatively high LOQ
(Table 2). Testosterone was detected at low levels in 32
out of 60 samples (detailed in Table 2). Most adrenal
steroids showed no significant change in concentra-
tion over the course of the second trimester (Fig. 3).
The exceptions were pregnenolone (P = 0.004), 17α-
hydroxyprogesterone (P < 0.001), 16α-hydroxyprogesterone
(P = 0.02) and corticosterone (P < 0.001), which decreased
significantly over the same period (Fig. 3). Since adrenal
Fig. 1 Fetal plasma ACTH, cortisol and CBG and adrenal weight during the second trimester. Data points from individual fetuses are shown
(circles for control and triangles for smoke-exposed, where groups are separated). Black lines indicate generalized linear regression, and grey fill
denotes the confidence interval (0.95) around an individual regression. There was no effect of fetal sex on levels of ACTH, cortisol or CBG (n = 60).
The interaction between fetal smoke exposure and gestational age on ACTH levels (a) approached significance, however (P = 0.052). Levels of
cortisol (b) and CBG (c) were unaffected by age or maternal smoking. Levels of CBG decreased between 12 and 20 weeks (c; P = 0.038). Combined
fetal adrenal weights increased between 12 and 20 weeks of gestation (d; P < 0.001; n = 109) with no effect of fetal sex or maternal smoking
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weight increases markedly during the second trimester, the
total adrenal content of measured, detectable steroids in-
creased over this period with the exception of cortico-
sterone which was unchanged (Additional file 1: Figure S1).
No differences between control male and female fetuses
were seen.
Maternal smoking was associated with altered intra-adrenal
levels of progesterone (P= 0.02), 17α-hydroxyprogesterone
(P = 0.02) and 16α-hydroxyprogesterone (P = 0.04) (Fig. 4;
expressed per adrenal pair). Each of these steroids showed
a significant interaction between smoking and gestational
age across the second trimester.
Tissue transcript and protein expression
mRNA transcripts
Most enzymes in the adrenal steroidogenic pathway
showed high levels of transcript expression throughout
the second trimester (Fig. 5a). Levels of CYP17A1, STAR,
CYP21A2 and CYP11A1, all of which are all involved in
the initial steps of steroid synthesis, were particularly
high. In contrast, levels of HSD3B and CYP11B2 tran-
scripts were low but detectable. Transcripts encoding
the ACTH receptor (MC2R), its accessory protein
MRAP and the key steroidogenic transcription factors
NR5A1 and GATA6 were also detectable in all adrenals
Fig. 2 Intra-adrenal steroid levels in the human fetal adrenal during the second trimester. Steroid levels, expressed as ng/mg of tissue, are shown
for each steroid measured (n = 60) and are arranged within the canonical steroidogenic pathways. The enzymes responsible for each conversion
are shown in grey boxes. Data points from individual fetuses are shown, and the limit of quantitation for each steroid is shown as a horizontal line.
Aldosterone, 17α-hydroxypregnenolone, DHEA and androstenedione were not detectable in any of the 60 samples. *The conversion of
11-deoxycorticosterone to aldosterone by CYP11B2 occurs via corticosterone and 18-hydroxycorticosterone as intermediates
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investigated. Most transcripts showed no significant
change in expression during the second trimester (Add-
itional file 2: Figure S2) with the exceptions of CYP11B2
(P = 0.003) and HSD3B (P = 0.004), which both increased
during this period (Fig. 5b), and POR (P = 0.03), which
increased during the initial part of the second trimester
(Fig. 5b). Similarly, there were no sex differences in any
of the transcript species measured apart from the key
sulphation enzyme SULT2A1, which was significantly
higher in males than in females (P = 0.04).
Maternal smoking was associated with increased ex-
pression of GATA6 and NR5A1 (Fig. 5b) in both sexes
(P < 0.001). Furthermore, maternal smoking was also as-
sociated with an increase in the variability (Additional
file 3: Figure S3) of STAR (P = 0.004) and CYP17A1 (P =
0.02) in males.
Aldosterone acts primarily through the NR3C2 recep-
tor in the kidney, and to determine whether the receptor
is expressed during the second trimester, NR3C2 levels
were measured in human fetal kidneys. Transcript levels
were variable but were detectable in all 56 human fetal
samples tested (Fig. 5c). There were no significant differ-
ences in transcript levels due to gestational age, fetal sex
or maternal smoking status.
Proteins
CYP11A1 (Fig. 6a and d) was primarily localized in the
adrenal fetal zone and transitional zone, with some im-
munoreactive cells also present in the definitive zone.
CYP17A1 was localized to the fetal zone and transition
zone (Fig. 6b), while CYP21A2 was most prominent in
the fetal zone although also detectable in the definitive
zone (Fig. 6c and d). CYP11A1 and CYP21A2 were co-
localized in some cells in the fetal zone, although many
cells expressed CYP21A2 alone while a few expressed
only CYP11A1 (Fig. 6d).
HSD3B was present primarily in cells of the adrenal
definitive zone (Fig. 6e), although a small number of
cells in the fetal zone in younger fetuses (12–13 weeks;
Fig. 6f ) also expressed the protein. These cells were
comparable in size to the other cells of the fetal zone
and were larger than the densely packed cells of the de-
finitive zone. HSD3B-expressing cells in the fetal zone
were not observed in the adrenals of fetuses older than
13 weeks.
Adrenal levels of CYP11A1, CYP17A1 and CYP21A2
protein, measured using Western blotting (Fig. 6g), were
similar between males and females, and no significant
differences were observed between control and smoke-
Fig. 3 Changes in intra-adrenal steroid levels (ng/mg of tissue) during the second trimester. Data points from individual fetuses are shown
(n = 60), and steroids which show a significant change with gestational age are indicated with an asterisk. Levels of pregnenolone (P = 0.004),
17α-hydroxyprogesterone (P < 0.001), 16α-hydroxyprogesterone (P = 0.02) and corticosterone (P < 0.001) decreased from 12 to 19 weeks. Generalized
linear regressions are shown as black lines with the corresponding confidence intervals (0.95) in grey
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exposed groups. Levels of CYP11A1 were not signifi-
cantly altered by gestational age (Fig. 6h), whereas con-
centrations of both CYP17A1 (Fig. 6i) and CYP21A2
(Fig. 6j) increased significantly between 12 and 19 weeks
of gestation, regardless of sex or smoke exposure (P =
0.04, and P = 0.004 respectively). HSD3B was barely de-
tectable by Western blotting and could not be reliably
quantified (not shown).
Discussion
The human fetal adrenal cortex and the placenta regu-
late most aspects of fetal steroid endocrinology, together
with the fetal liver and testes [25]. Normal development
of the adrenal gland is therefore essential in maintaining
fetal levels of glucocorticoids, mineralocorticoids and es-
trogens. Failure of normal adrenal development can lead
to congenital adrenal hyperplasia (most commonly
through loss of 21-hydroxylase activity and leading to
disorders of sex development [26, 27]), salt-wasting dis-
orders and adrenal insufficiency in the newborn [3, 12,
28, 29]. In this study, we have used a large cohort (up to
109 fetuses) of well-characterized, normal, human fetal
samples to detail changes in fetal adrenal steroidogenesis
during the second trimester, a critical time for fetal
growth, development and sex differentiation. We show
that the fetal adrenal produces cortisol throughout the
second trimester, possibly from placental progesterone
[27]. However, we also show that aldosterone is not syn-
thesized in detectable amounts during this period, which
may be of importance in understanding pre-term neo-
natal salt wasting. Maternal smoking changes fetal
ACTH levels, but this is not accompanied by down-
stream effects on the primary adrenal steroids.
Together, the concentrations of intra-adrenal steroids
and expression of steroidogenic enzymes indicate that
the fetal adrenal is highly active throughout the second
trimester in the human. In our studies, the enzymes ne-
cessary for adrenal steroid synthesis were expressed by
week 12 of gestation and mostly at relatively high levels
apart from HSD3B and CYP11B2, which were low at this
stage. Low levels of HSD3B and CYP11B2 transcripts in
the late second/early third trimester have also been re-
ported previously [9, 30]. Despite low HSD3B transcript
and protein expression, however, the Δ4 steroids proges-
terone, 17α-hydroxyprogesterone and cortisol were
present in significant amounts throughout the second
trimester. The fetal adrenals also generated significant
amounts of 16α-hydroxyprogesterone, as reported previ-
ously [31, 32], due to the relatively high 16α-
hydroxylation activity of human CYP17A1 [33]. The
presence of these Δ4 steroids in such high amounts may
occur because HSD3B enzyme activity does not reflect
transcript or protein levels or because placental proges-
terone, derived from the circulation, is being converted
in the fetal adrenals as previously suggested [13, 34]. Ele-
vated amniotic fluid levels of 17α-hydroxyprogesterone
have been reported to be a reasonable indicator of 21-
hydroxylase deficiency and congenital adrenal hyperpla-
sia in the mid-gestation fetus [35, 36]. While molecular
methods are now more commonly used to diagnose con-
genital adrenal hyperplasia [37], our results show that
fetal adrenal steroid concentrations do not change mark-
edly after 12 weeks. It is, therefore, possible that amni-
otic fluid from early second trimester fetuses could be
used to confirm diagnosis of 21-hydroxylase deficiency.
Salt-wasting disorders frequently occur in extreme
pre-term neonates [38], and it has been suggested that
this may be due to low expression of the mineralocortic-
oid receptor (NR3C2) in the pre-term kidney [39]. The
results described here suggest, however, that neonatal
salt-wasting syndrome in pre-term infants may occur be-
cause of a limited capacity of the fetal adrenal to gener-
ate aldosterone. This is consistent with earlier studies
showing that tissue from second trimester human adre-
nals has little or no capability to produce aldosterone in
vitro from tritiated substrate [40, 41]. It is also consistent
Fig. 4 The effects of maternal smoking on intra-adrenal steroid
levels during the second trimester. Measurements from individual
fetuses are shown. Steroids are expressed as ng per total combined
adrenal weight (n = 60). Maternal smoking was associated with altered
intra-adrenal levels of three of the 19 steroids measured during the
second trimester: progesterone (P = 0.02), 17α-hydroxyprogesterone (P
= 0.02) and 16α-hydroxyprogesterone (P = 0.04) with P values corre-
sponding to the interaction between smoke exposure and gesta-
tional age. Black lines show generalized linear regressions, and grey fill
shows the confidence interval (0.95) around the regression
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with reports that pre-term neonates (26–32 weeks gesta-
tion) have normal sensitivity to aldosterone but reduced
capacity to secrete the steroid [5] and with the demon-
stration (Fig. 5c) that the human fetal kidney consist-
ently expresses NR3C2 during the late first and the
second trimester. Both CYP11B2 (aldosterone synthase)
and CYP11B1 can catalyse the conversion of 11-
deoxycorticosterone to corticosterone, although further
conversion to aldosterone, via the intermediate 18-
hydroxycorticosterone, is only performed by CYP11B2
Fig. 5 Expression levels of key mRNA transcripts in the human fetal adrenal and fetal kidney during the second trimester. a Overall adrenal transcript
levels (relative to housekeeping genes (HKGs)) during the second trimester are shown on a log scale. Data points represent mRNA levels in individual
fetuses. b Changes in adrenal transcript levels during the second trimester, due to fetal sex and/or maternal smoking. Expression of CYP11B2
(P = 0.003, n = 56) and HSD3B (P = 0.004, n = 58) increased between 12 and 19 weeks of gestation, while POR (P = 0.03, n = 60) increased during
the initial phase of the trimester. Other transcripts did not change significantly during the second trimester. Black lines show the generalized
linear regression, and grey fill denotes the confidence interval (0.95) around the regression. Levels of SULT2A1 were significantly different between
male and female fetuses, P = 0.04 (n = 58), but there was no effect of maternal smoking (not shown). Maternal smoking was associated with increased
levels of the transcription factor GATA6 (P < 0.001; n = 56) in both male and female fetuses and increased levels of NR5A1 (P = 0.04; n = 58) in male
fetuses compared to control males. There were no other effects of age or smoking on transcript levels. CF control females, SF smoke-exposed females,
CM control males, SM smoke-exposed males. c Transcript levels of the mineralocorticoid receptor NR3C2 in the human fetal kidney (n = 56; from 7 to
20 weeks of gestation). NR3C2 transcript expression did not differ significantly due to fetal age or sex, or maternal smoking. In all datasets, the
horizontal line corresponds to the mean expression, and each data point corresponds to an individual fetus
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[42–44]. Therefore, the absence of detectable fetal adrenal
aldosterone in this study is likely a reflection of the low
expression of CYP11B2 as previously predicted [13].
Human fetal adrenal glucocorticoid and androgen pro-
duction is dependent on ACTH released by the fetal pi-
tuitary during the second trimester [13]. It has also been
proposed that expression of the enzyme HSD3B and
interaction with fetal ACTH (through altered negative
feedback) is key to understanding the regulation of fetal
adrenal steroid production [1]. Goto et al. [1] have re-
ported that transiently elevated HSD3B expression occurs
towards the end of the first trimester, leading to early cor-
tisol biosynthesis. They suggest that this has a negative
feedback effect on the fetal pituitary, reducing ACTH
stimulation of fetal adrenal androgen secretion and
thereby protecting female fetuses from masculinization.
Our results extend the work of Goto et al [1] into the sec-
ond trimester and show that the fetal adrenal continues to
make cortisol throughout this period, despite the loss of
HSD3B activity. This means that ACTH will remain under
negative feedback control during the second trimester.
One complication of the hypothesis of Goto et al. [1] is
Fig. 6 Steroidogenic enzyme localization and expression in the fetal adrenal. a CYP11A1 (brown) was localized primarily in the inner fetal zone
(yellow arrow) with some cells in the definitive zone (black arrow) exhibiting weak immunostaining. b CYP17A1 (brown) was expressed throughout the
adrenal, while (c) CYP21A2 (brown) was localized primarily in the fetal zone (yellow arrow), although protein expression was also seen in the definitive
zone (black arrows, inset). d CYP11A1 (cyan) and CYP21A2 (magenta) co-localize in some cells of the fetal zone (yellow arrow), but most cells only
express one of these enzymes with CYP21A2 the predominant enzyme. e HSD3B was predominantly localized to the outer definitive zone (black arrow),
although it was also present in some cells within the fetal zone of adrenals at 12 weeks of gestation (f; yellow arrow). These HSD3B-positive cells in the
fetal zone were not observed after 13 weeks of gestation. g Representative Western blot showing CYP11A1, CYP17A1, CYP21A2 and the loading control
β-actin. Molecular weight markers are labelled on the left of the image. h–j Expression levels of CYP11A1, CYP17A1 and CYP21A2 protein in the fetal
adrenal during the second trimester. Data points from individual fetuses are shown. Black lines show the generalized linear regression, and grey fill
denotes the confidence interval (0.95) around the regression. Expression of CYP11A1 was unaffected by gestational age, while both CYP17A1 (P = 0.004)
and CYP21A2 (P = 0.04) showed increased expression between 12 and 19 weeks
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that higher HSD3B activity during the first trimester will
tend to favour androgen production, which will then be in
a balance between enzyme activity and altered negative
feedback. This is particularly pertinent as human
CYP17A1 has poor C17-20 lyase activity with 17α-
hydroxyprogesterone as substrate [44], meaning that ad-
renal Δ4 androgens are only likely to be generated de novo
(under ACTH regulation) rather than from placental pro-
gesterone. Adrenal androstenedione is present at the end
of the first trimester at relatively high levels [1, 11] but not
in the second trimester. This suggests that adrenal Δ4 an-
drogen production, by both sexes, may be higher during
the first trimester, reflecting HSD3B activity rather than
altered negative feedback.
The presence of adrenal cortisol throughout the
second trimester also has implications for treatment of
congenital adrenal hyperplasia. This condition arises
through deficiency of one of the enzymes involved in
cortisol synthesis, commonly 21-hydroxylase. In turn,
this leads to increased ACTH levels through impaired
negative feedback and to increased adrenal androgen
production. The condition is normally treated through
administration of dexamethasone from the first trimester
until birth. It has been suggested, however, that dexa-
methasone treatment in these cases may only be neces-
sary in the first half of pregnancy [45]. One proposed
reason is that fetal cortisol is absent (based on HSD3B
expression) during the second trimester and that fetal
ACTH would not normally be under negative feedback
control during this period. The demonstration here that
the fetal adrenal produces cortisol throughout the sec-
ond trimester is of direct relevance, therefore, and sug-
gests that normal homeostatic feedback regulation
remains in place at all times after the first trimester.
One possible confounding factor in these studies is the
effect of the termination regime on fetal ACTH and ster-
oid levels. RU486 acts as an antagonist at both the proges-
terone and glucocorticoid receptors, and in non-pregnant
subjects daily administration will increase ACTH and
cortisol over a 7-day period [46]. The dose of RU486 used
clinically in this study, however, was 200 mg/patient (aver-
age 2.7 mg/kg), which is less than the dose required for
anti-glucocorticoid action (4.5 mg/kg) [47]. Furthermore,
while RU486 transfers readily across the placenta, fetal
plasma concentrations of the drug are 0.1–10% of those
found in the maternal circulation [48, 49], and it is highly
unlikely that fetal drug concentrations will reach the
threshold levels required to affect the fetal HPA axis. This
is borne out by an earlier study which reported that use of
RU486 during terminations (at 600 mg, three times the
dose used in this study) had no effect on fetal or maternal
plasma cortisol concentrations [48]. Similarly, RU486 is
reported to have no effect on placental ACTH during first
or second trimester termination [50].
The adrenal gland is highly zonated both morpho-
logically and functionally. Earlier studies by Jaffe and
colleagues [13, 51–53] developed the concept, based
on spatial distribution of steroidogenic enzymes, that
the human fetal adrenal in the third trimester is com-
posed of three functional zones which are analogous
to the adult cortical zones. They proposed that the
definitive, transitional and fetal zones are analogous
to the zona glomerulosa, the zona fasciculata and the
zona reticularis respectively. Our immunolocalization
results generally agree with these and other studies
[7, 9, 10, 13, 51–53] and suggest that functional zon-
ation is present from as early as 12 weeks. These im-
munolocalization studies show that the fetal zone is
the main site of CYP11A1, CYP17A1 and CYP21A2
expression during the second trimester. This means
that the fetal zone is likely to be the main site of
DHEA production and of de novo steroid synthesis.
Synthesis of other adrenal steroids requires HSD3B
activity, however, which is localized primarily in the
definitive zone. This means either that steroid intermedi-
ates move between the adrenal zones to facilitate de novo
synthesis or that Δ4 steroid synthesis depends largely on
placental progesterone as described above. Given the low
levels of adrenal HSD3B during the second trimester and
the intense vascularization of the fetal zone, which would
favour delivery of steroid substrate from the circulation,
use of placental progesterone appears the more likely
route [34]. The presence of all components of the
steroidogenic pathway in the adrenal also means, however,
that de novo synthesis is likely to contribute to overall
steroid levels and to androgen levels in particular, as
discussed above. Our co-localization studies show that,
within the fetal zone, different cells express different
combinations of steroidogenic enzymes. This may be
because they represent different populations of cells, or it
possibly may be due to the local environment of the cell.
The effect of maternal smoking on fetal adrenal func-
tion and HPA axis development is most clearly seen in
the association between maternal smoking and sudden
infant death syndrome [54], which may be linked to ad-
renal dysfunction [55]. Our results show that maternal
smoking is associated with altered circulating fetal
ACTH (P = 0.052), although there was no effect on
plasma cortisol levels. Intra-adrenal fetal cortisol con-
centrations were also unaffected by smoke exposure,
which suggests that there is a reduced sensitivity of the
adrenal to ACTH through down-regulation of either the
receptor or second messenger systems. These data are
consistent with a previous study showing increased
ACTH, but unchanged cortisol, at birth following expos-
ure to maternal smoking in utero [16]. These pro-
grammed changes in adrenal sensitivity to ACTH
induced by maternal smoking may be of importance
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after birth if ACTH levels return to normal in exposed
neonates but adrenal sensitivity remains reduced. Con-
sistent with this hypothesis, neonatal cortisol levels and
cortisol response to stress are reported to be significantly
reduced in the first month after birth following exposure
to maternal smoking in utero [56].
Maternal smoking is also associated with altered whole-
adrenal levels (nanograms/adrenal pair) of progesterone,
17α-hydroxyprogesterone and 16α-hydroxyprogesterone
across the second trimester. As discussed above, it is likely
that Δ4 steroids in the fetal adrenal are derived, at least in
part, from placental progesterone, and so these changes
may reflect alterations in placental activity in response to
maternal smoking. A number of studies have shown that
maternal smoking can alter placental function and may re-
duce placental progesterone concentrations [57]. We have
reported that circulating maternal progesterone is not
clearly affected by maternal smoking [58]. However, if
plasma concentrations in the fetus more closely represent
placental production, then this may have a knock-on effect
on total adrenal steroid levels.
The most marked effects of maternal smoking on the
fetal adrenal were increased levels of NR5A1 and GATA6
transcripts. NR5A1 encodes steroidogenic factor 1 (SF-
1), which is a nuclear receptor transcription factor es-
sential for development and function of the adrenals and
gonads [8]. Disruption of SF-1, unless severe, has greater
clinical effects on the gonads than the adrenals [59], but
it is unclear what effects overexpression of SF-1 in utero
will have on adrenal development in the human. Overex-
pression of SF-1 in mice leads to an increase in adrenal
size through increased commitment of precursors to the
steroidogenic lineage [14, 60], although maternal smok-
ing had no significant effects on human fetal adrenal
weight in our study. It remains to be seen, however,
whether the morphological and cellular composition of
the fetal adrenals is affected by smoking. GATA6 is a
zinc finger transcription factor which works in concert
with SF-1 [61] to activate steroidogenic enzyme expres-
sion in general and HSD3B in particular [62–64]. While
no significant changes in steroidogenic enzyme expres-
sion were seen in the smoke-exposed group, the in-
creased variability in STAR and CYP17A1 expression
may be related to altered transcription factor expression.
Conclusions
Along with the placenta, the fetal adrenal acts to regu-
late fetal steroid endocrinology, and normal fetal devel-
opment of the adrenals is essential for post-natal health.
Mapping the interactions between placenta, adrenals
and other endocrine organs (e.g. the testes) is essential,
therefore, to understand how these processes can be
dysregulated. This study is the first to comprehensively
document the changes in adrenal steroid levels and
steroidogenic enzyme expression throughout the second
trimester and shows that a combination of substrate
availability, enzyme expression and enzyme specificity
regulates adrenal steroid production. Critically, this
study shows that the fetal adrenals do not synthesize de-
tectable levels of aldosterone, which is likely to explain
pre-term salt-wasting conditions. They do, however,
synthesize cortisol throughout the second trimester,
which indicates that fetal ACTH secretion is under in-
hibitory regulation by the adrenal during this period
with implications for our understanding and treatment
of congenital adrenal hyperplasia. Maternal smoking did
not have marked effects on fetal adrenal steroidogenic
function, but it did alter fetal ACTH levels, which may
trigger homeostatic mechanisms in the adrenal leading
to knock-on effects in the neonate.
Additional files
Additional file 1: Figure S1. Changes in whole intra-adrenal steroid
levels (ng/adrenal pair) during the second trimester. Data points from
individual fetuses are shown (n = 60). All detectable steroid levels increase
significantly with gestational age (P < 0.001) with the exception of
corticosterone. Generalized linear regressions are shown as black lines
with the corresponding confidence intervals (0.95) in grey. (TIF 80 kb)
Additional file 2: Figure S2. Age-dependent changes in adrenal
expression of mRNA transcripts encoding factors involved in steroid
synthesis. CYP11B2, HSD3B and POR are also shown in Fig. 5 and have
been included here for completeness. Transcript levels are plotted
relative to housekeeping genes (HKGs), and each point represents data
from an individual fetus. Black lines denote a generalized linear
regression, and grey fill denotes the confidence interval (0.95) around the
regression. (TIF 310 kb)
Additional file 3: Figure S3. Effect of maternal smoking on STAR and
CYP17A1 transcript levels in the fetal adrenal during the second trimester.
Maternal smoking was associated with an increase in the variability
(Levene’s test) of transcript expression of STAR (P = 0.004) and CYP17A1
(P = 0.02), in male smoke-exposed (SE) fetuses compared to male controls
(C). Each point represents data from an individual fetus and transcript
levels are expressed relative to HKGs. Black lines denote a generalized
linear regression, and grey fill denotes the confidence interval (0.95)
around the regression. Data points for females are shown in the left of
each panel and males on the right. Data points for controls are shown on
the top of each panel and smoke-exposed on the bottom. (TIF 339 kb)
Abbreviations
ACTH: Adrenocorticotropic hormone; CBG: Corticosteroid-binding globulin;
CRL: Crown-rump length; DHEA: Dehydroepiandrosterone;
DHEAS: Dehydroepiandrosterone sulphate; HPA: Hypothalamo-pituitary-adrenal;
IS: Internal standard; LOD: Limit of detection; LOQ: Limit of quantitation;
PMM1: Phosphomannomutase 1; RSD: Relative standard deviation; S/N: Signal-
to-noise ratio; SEM: Standard error of the mean; SF-1: Steroidogenic factor 1;
TBP: TATA box binding protein
Acknowledgements
We are grateful to Margaret Fraser, Linda Robertson, Ana Monteiro, Lynne
Fleming and Sam Flannigan for expert technical assistance and to the Ian
Fraser Cytometry Centre, University of Aberdeen, for the multiplex assay. We
thank Karl Burgess for advice in developing the steroid LC/MS system and
Ian Mason for provision of antibodies. The staff at Grampian NHS Pregnancy
Counselling Service were essential for fetal collection. We also thank Serena
Banh and Natasha Walker (University of Aberdeen) for the human fetal
kidney data shown in Fig. 5c.
Johnston et al. BMC Medicine  (2018) 16:23 Page 14 of 16
Funding
This study was supported by grants from the Medical Research Council
(MR/L010011/1 to PAF and PJOS and MR/K501335/1 to MB, PAF and PJOS),
the Canadian Institutes of Health Research (MOP-111102 to GLH), a Canada
Research Chair in Reproductive Health (to GLH), and a post-doctoral fellowship
from the Fonds de Recherche du Québec en Santé and the Michael Smith
Foundation for Health Research (to MS).
Availability of data and materials
The datasets generated and/or analysed during the current study are all
presented within the manuscript and its additional files.
Authors’ contributions
PAF and PJOS conceived and designed the study, analysed and interpreted
the data and drafted and revised the article. ZCJ conceived and designed
the study, acquired, analysed and interpreted the data and drafted and
revised the article. MB and SB conceived and designed the study and
analysed and interpreted the data. PF, US, DH, MS, GLH and PK acquired and
interpreted the data. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The collection of fetal material was approved by the NHS Grampian Research
Ethics Committee (REC 04/S0802/21 and REC 15/NS/0123).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Institute of Biodiversity, Animal Health & Comparative Medicine, College of
Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow G61 1QH,
UK. 2Institute of Medical Sciences, School of Medicine, Medical Sciences &
Nutrition, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
3Institute of Applied Health Sciences, School of Medicine, Medical Sciences &
Nutrition, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
4Department of Cellular and Physiological Sciences, Life Sciences Institute,
University of British Columbia, British Columbia V6T 1Z3, Canada. 5Centre for
Endocrinology, William Harvey Research Institute, Barts and the London,
Queen Mary University of London, Charterhouse Square, London EC1M 6BQ,
UK.
Received: 7 August 2017 Accepted: 18 January 2018
References
1. Goto M, Hanley KP, Marcos J, Wood PJ, Wright S, Postle AD, Cameron IT,
Mason JI, Wilson DI, Hanley NA. In humans, early cortisol biosynthesis
provides a mechanism to safeguard female sexual development. J Clin
Investig. 2006;116:953–60.
2. Rainey WE, Rehman KS, Carr BR. The human fetal adrenal: making adrenal
androgens for placental estrogens. Semin Reprod Med. 2004;22:327–36.
3. Lekarev O, New MI. Adrenal disease in pregnancy. Best Pract Res Clin
Endocrinol Metab. 2011;25:959–73.
4. Seckl JR. Glucocorticoid programming of the fetus; adult phenotypes and
molecular mechanisms. Mol Cell Endocrinol. 2001;185:61–71.
5. Martinerie L, Pussard E, Yousef N, Cosson C, Lema I, Husseini K, Mur S,
Lombes M, Boileau P. Aldosterone-signaling defect exacerbates sodium
wasting in very preterm neonates: the Premaldo Study. J Clin Endocrinol
Metab. 2015;100:4074–81.
6. Fernandez EF, Watterberg KL. Relative adrenal insufficiency in the preterm
and term infant. J Perinatol. 2009;29 Suppl 2:S44–49.
7. Narasaka T, Suzuki T, Moriya T, Sasano H. Temporal and spatial distribution
of corticosteroidogenic enzymes immunoreactivity in developing human
adrenal. Mol Cell Endocrinol. 2001;174:111–20.
8. Hanley NA, Rainey WE, Wilson DI, Ball SG, Parker KL. Expression profiles of
SF-1, DAX1, and CYP17 in the human fetal adrenal gland: potential
interactions in gene regulation. Mol Endocrinol. 2001;15:57–68.
9. Naccache A, Louiset E, Duparc C, Laquerriere A, Patrier S, Renouf S, Gomez-
Sanchez CE, Mukai K, Lefebvre H, Castanet M. Temporal and spatial
distribution of mast cells and steroidogenic enzymes in the human fetal
adrenal. Mol Cell Endocrinol. 2016;434:69–80.
10. Folligan K, Bouvier R, Targe F, Morel Y, Trouillas J. Histological and molecular
study of fetal human adrenal cortex (12-36 wk). Ann Endocrinol (Paris).
2005;66:519–26.
11. Savchuk I, Morvan ML, Antignac JP, Gemzell-Danielsson K, Le Bizec B, Soder
O, Svechnikov K. Androgenic potential of human fetal adrenals at the end
of the first trimester. Endocr Connect. 2017;6:348–59.
12. Ishimoto H, Jaffe RB. Development and function of the human fetal adrenal
cortex: a key component in the feto-placental unit. Endocr Rev. 2011;32:317–55.
13. Mesiano S, Jaffe RB. Developmental and functional biology of the primate
fetal adrenal cortex. Endocr Rev. 1997;18:378–403.
14. Cornelius MD, Day NL. Developmental consequences of prenatal tobacco
exposure. Curr Opin Neurol. 2009;22:121–5.
15. O'Shaughnessy PJ, Monteiro A, Bhattacharya S, Fowler PA. Maternal
smoking and fetal sex significantly affect metabolic enzyme expression in
the human fetal liver. J Clin Endocrinol Metab. 2011;96:2851–60.
16. McDonald SD, Walker M, Perkins SL, Beyene J, Murphy K, Gibb W, Ohlsson
A. The effect of tobacco exposure on the fetal hypothalamic–pituitary–
adrenal axis. Br J Obstet Gynaecol. 2006;113:1289–95.
17. Kanaka-Gantenbein C. Fetal origins of adult diabetes. Ann N Y Acad Sci.
2010;1205:99–105.
18. Xita N, Tsatsoulis A. Fetal origins of the metabolic syndrome. Ann N Y Acad
Sci. 2010;1205:148–55.
19. O'Shaughnessy PJ, Baker PJ, Monteiro A, Cassie S, Bhattacharya S, Fowler PA.
Developmental changes in human fetal testicular cell numbers and
messenger ribonucleic acid levels during the second trimester. J Clin
Endocrinol Metab. 2007;92:4792–801.
20. Hammond GL, Lähteenmäki PLA. A versatile method for the determination
of serum cortisol binding globulin and sex hormone binding globulin
binding capacities. Clin Chim Acta. 1983;132:101–10.
21. Schloms L, Storbeck KH, Swart P, Gelderblom WC, Swart AC. The influence
of Aspalathus linearis (Rooibos) and dihydrochalcones on adrenal
steroidogenesis: quantification of steroid intermediates and end products in
H295R cells. J Steroid Biochem Mol Biol. 2012;128:128–38.
22. O'Shaughnessy PJ, Willerton L, Baker PJ. Changes in Leydig cell gene
expression during development in the mouse. Biol Reprod. 2002;66:966–75.
23. Baker PJ, O'Shaughnessy PJ. Expression of prostaglandin D synthetase
during development in the mouse testis. Reproduction. 2001;122:553–9.
24. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative
reverse transcription-PCR data: a model-based variance estimation approach
to identify genes suited for normalization, applied to bladder and colon
cancer data sets. Cancer Res. 2004;64:5245–50.
25. O'Shaughnessy PJ, Monteiro A, Bhattacharya S, Fraser MJ, Fowler PA.
Steroidogenic enzyme expression in the human fetal liver and potential role
in the endocrinology of pregnancy. Mol Hum Reprod. 2013;19:177–87.
26. Kamrath C, Hochberg Z, Hartmann MF, Remer T, Wudy SA. Increased
activation of the alternative “backdoor” pathway in patients with 21-
hydroxylase deficiency: evidence from urinary steroid hormone analysis. J
Clin Endocrinol Metab. 2012;97:E367–375.
27. Fukami M, Homma K, Hasegawa T, Ogata T. Backdoor pathway for
dihydrotestosterone biosynthesis: implications for normal and abnormal
human sex development. Dev Dyn. 2013;242:320–9.
28. El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet.
2017;390:2194–210.
29. Witchel SF, Azziz R. Congenital adrenal hyperplasia. J Pediatr Adolesc
Gynecol. 2011;24:116–26.
30. Pezzi V, Mathis JM, Rainey WE, Carr BR. Profiling transcript levels for
steroidogenic enzymes in fetal tissues. J Steroid Biochem Mol Biol. 2003;87:
181–9.
31. Swart P, Swart AC, Waterman MR, Estabrook RW, Mason JI. Progesterone 16
alpha-hydroxylase activity is catalyzed by human cytochrome P450 17
alpha-hydroxylase. J Clin Endocrinol Metab. 1993;77:98–102.
32. Arlt W, Martens JW, Song M, Wang JT, Auchus RJ, Miller WL. Molecular
evolution of adrenarche: structural and functional analysis of p450c17 from
four primate species. Endocrinology. 2002;143:4665–72.
Johnston et al. BMC Medicine  (2018) 16:23 Page 15 of 16
33. Storbeck KH, Kolar NW, Stander M, Swart AC, Prevoo D, Swart P. The
development of an ultra performance liquid chromatography-coupled
atmospheric pressure chemical ionization mass spectrometry assay for
seven adrenal steroids. Anal Biochem. 2008;372:11–20.
34. Macnaughton MC, Taylor T, McNally EM, Coutts JR. The effect of synthetic
ACTH on the metabolism of [4-14C]-progesterone by the previable human
fetus. J Steroid Biochem. 1977;8:499–504.
35. Wudy SA, Dorr HG, Solleder C, Djalali M, Homoki J. Profiling steroid
hormones in amniotic fluid of midpregnancy by routine stable isotope
dilution/gas chromatography-mass spectrometry: reference values and
concentrations in fetuses at risk for 21-hydroxylase deficiency. J Clin
Endocrinol Metab. 1999;84:2724–8.
36. Forest MG, Betuel H, Couillin P, Boue A. Prenatal diagnosis of congenital
adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency by steroid
analysis in the amniotic fluid of mid-pregnancy: comparison with HLA
typing in 17 pregnancies at risk for CAH. Prenat Diagn. 1981;1:197–207.
37. Tardy-Guidollet V, Menassa R, Costa JM, David M, Bouvattier-Morel C,
Baumann C, Houang M, Lorenzini F, Philip N, Odent S, et al. New
management strategy of pregnancies at risk of congenital adrenal
hyperplasia using fetal sex determination in maternal serum: French cohort
of 258 cases (2002-2011). J Clin Endocrinol Metab. 2014;99:1180–8.
38. Barrington KJ. Management during the first 72 h of age of the periviable
infant: an evidence-based review. Semin Perinatol. 2014;38:17–24.
39. Martinerie L, Viengchareun S, Delezoide AL, Jaubert F, Sinico M, Prevot S,
Boileau P, Meduri G, Lombes M. Low renal mineralocorticoid receptor
expression at birth contributes to partial aldosterone resistance in neonates.
Endocrinology. 2009;150:4414–24.
40. Nelson HP, Kuhn RW, Deyman ME, Jaffe RB. Human fetal adrenal definitive
and fetal zone metabolism of pregnenolone and corticosterone: alternate
biosynthetic pathways and absence of detectable aldosterone synthesis. J
Clin Endocrinol Metabol. 1990;70:693–8.
41. Dufau ML, Villee DB. Aldosterone biosynthesis by human fetal adrenal in
vitro. Biochem Biophys Acta. 1969;176:637–40.
42. Portrat-Doyen S, Tourniaire J, Richard O, Mulatero P, Aupetit-Faisant B,
Curnow KM, Pascoe L, Morel Y. Isolated aldosterone synthase deficiency
caused by simultaneous E198D and V386A mutations in the CYP11B2 gene.
J Clin Endocrinol Metabol. 1998;83:4156–61.
43. Schiffer L, Anderko S, Hannemann F, Eiden-Plach A, Bernhardt R. The
CYP11B subfamily. J Steroid Biochem Mol Biol. 2015;151:38–51.
44. Strushkevich N, Gilep AA, Shen L, Arrowsmith CH, Edwards AM, Usanov SA,
Park HW. Structural insights into aldosterone synthase substrate specificity
and targeted inhibition. Mol Endocrinol. 2013;27:315–24.
45. Hanley NA, Arlt W. The human fetal adrenal cortex and the window of
sexual differentiation. Trends Endocrinol Metab. 2006;17:391–7.
46. Block T, Petrides G, Kushner H, Kalin N, Belanoff J, Schatzberg A.
Mifepristone plasma level and glucocorticoid receptor antagonism
associated with response in patients with psychotic depression. J Clin
Psychopharmacol. 2017;37:505–11.
47. Mifegyne. http://www.medicines.org.uk/emc/medicine/617. Accessed
7 Dec 2017.
48. Hill NC, Selinger M, Ferguson J, MacKenzie IZ. The placental transfer of
mifepristone (RU 486) during the second trimester and its influence upon
maternal and fetal steroid concentrations. Br J Obstet Gynaecol. 1990;97:
406–11.
49. Ishii A, Zaitsu K, Kusano M, Asano T, Ogawa T, Hattori H, Seno H.
Identification and quantitation of mifepristone and its N-demethyl
metabolite in the plasma of an aborted fetus by liquid chromatography–
quadrupole–time-of-flight–mass spectrometry (LC–Q–TOFMS) and ultra-
performance liquid chromatography–tandem mass spectrometry (UPLC–
MS–MS). Forensic Toxicol. 2015;33:409–12.
50. Cooper ES, Greer IA, Brooks AN. Placental proopiomelanocortin gene
expression, adrenocorticotropin tissue concentrations, and immunostaining
increase throughout gestation and are unaffected by prostaglandins,
antiprogestins, or labor. J Clin Endocrinol Metab. 1996;81:4462–9.
51. Coulter CL, Jaffe RB. Functional maturation of the primate fetal adrenal in
vivo: 3. Specific zonal localization and developmental regulation of CYP21A2
(P450c21) and CYP11B1/CYP11B2 (P450c11/aldosterone synthase) lead to
integrated concept of zonal and temporal steroid biosynthesis.
Endocrinology. 1998;139:5144–50.
52. Mesiano S, Coulter CL, Jaffe RB. Localization of cytochrome P450 cholesterol
side-chain cleavage, cytochrome P450 17 alpha-hydroxylase/17, 20-lyase,
and 3 beta-hydroxysteroid dehydrogenase isomerase steroidogenic
enzymes in human and rhesus monkey fetal adrenal glands: reappraisal of
functional zonation. J Clin Endocrinol Metab. 1993;77:1184–9.
53. Coulter CL, Goldsmith PC, Mesiano S, Voytek CC, Martin MC, Mason JI, Jaffe
RB. Functional maturation of the primate fetal adrenal in vivo. II. Ontogeny
of corticosteroid synthesis is dependent upon specific zonal expression of 3
beta-hydroxysteroid dehydrogenase/isomerase. Endocrinology. 1996;137:
4953–9.
54. Fleming P, Blair PS. Sudden Infant Death Syndrome and parental smoking.
Early Hum Dev. 2007;83:721–5.
55. Gozzi TG, Harris NP, McGown IN, Cowley DM, Cotterill AM, Campbell PE,
Anderson PK, Warne GL. Autopsy diagnosis of 21-hydroxylase deficiency
CAH in a case of apparent SIDS. Pediatr Dev Pathol. 2005;8:397–401.
56. Stroud LR, Papandonatos GD, Rodriguez D, McCallum M, Salisbury AL,
Phipps MG, Lester B, Huestis MA, Niaura R, Padbury JF, Marsit CJ. Maternal
smoking during pregnancy and infant stress response: test of a prenatal
programming hypothesis. Psychoneuroendocrinology. 2014;48:29–40.
57. Piasek M, Blanuša M, Kostial K, Laskey JW. Placental cadmium and
progesterone concentrations in cigarette smokers. Reprod Toxicol. 2001;15:
673–81.
58. Huuskonen P, Amezaga MR, Bellingham M, Jones LH, Storvik M, Hakkinen M,
Keski-Nisula L, Heinonen S, O'Shaughnessy PJ, Fowler PA, Pasanen M. The
human placental proteome is affected by maternal smoking. Reprod
Toxicol. 2016;63:22–31.
59. Suntharalingham JP, Buonocore F, Duncan AJ, Achermann JC. DAX-1
(NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease. Best
Pract Res Clin Endocrinol Metab. 2015;29:607–19.
60. Zubair M, Oka S, Parker KL, Morohashi K. Transgenic expression of Ad4BP/
SF-1 in fetal adrenal progenitor cells leads to ectopic adrenal formation. Mol
Endocrinol. 2009;23:1657–67.
61. Tremblay JJ, Viger RS. Novel roles for GATA transcription factors in the
regulation of steroidogenesis. J Steroid Biochem Mol Biol. 2003;85:291–8.
62. Martin LJ, Tremblay JJ. The human 3β-hydroxysteroid dehydrogenase/Δ5-Δ4
isomerase type 2 promoter is a novel target for the immediate early orphan
nuclear receptor Nur77 in steroidogenic cells. Endocrinology. 2005;146:861–9.
63. Mamluk R, Greber Y, Meidan R. Hormonal regulation of messenger
ribonucleic acid expression for steroidogenic factor-1, steroidogenic acute
regulatory protein, and cytochrome P450 side-chain cleavage in bovine
luteal cells. Biol Reprod. 1999;60:628–34.
64. Jimenez P, Saner K, Mayhew B, Rainey WE. GATA-6 is expressed in the
human adrenal and regulates transcription of genes required for adrenal
androgen biosynthesis. Endocrinology. 2003;144:4285–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Johnston et al. BMC Medicine  (2018) 16:23 Page 16 of 16
